[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f7yoqoX60fmLD_dgTs1ULpr82smLo7fmo9VKDOOZmkDw":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":45,"rows":52},"Joslin Diabetes Center",[4],79,false,13,5,6889,2,60,[14,16,19,21,24,27,29,31],{"name":15,"count":8},"Obesity",{"name":17,"count":18},"Type 1 Diabetes",12,{"name":20,"count":18},"Hypoglycemia",{"name":22,"count":23},"Diabetes",10,{"name":25,"count":26},"Type 2 Diabetes",8,{"name":28,"count":26},"Type 2 Diabetes Mellitus",{"name":30,"count":9},"Type 1 Diabetes Mellitus",{"name":32,"count":33},"Insulin Resistance",4,[35,40],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT06986603","Glucagon Dose-Response in Patients With Post-Bariatric Hypoglycemia","2026-06-01","Glucagon for",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT04428723","Mechanisms of Hypoglycemia in Patients Without Diabetes","2026-12","Blood sample for DNA analysis",[46,47,48,49,50,51],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[53,79,99,126,155,173,198,216,241,265,329,355,373,399,417,442,467,493,516,541],{"intervention":39,"totalTrials":54,"cells":55},1,{"EARLY_PHASE1":56,"PHASE1":59,"PHASE2":61,"PHASE3":63,"PHASE4":65,"NA":77},{"trials":57,"activeCount":58},[],0,{"trials":60,"activeCount":58},[],{"trials":62,"activeCount":58},[],{"trials":64,"activeCount":58},[],{"trials":66,"activeCount":54,"soonestReadout":38},[67],{"nctId":36,"briefTitle":37,"status":68,"phases":69,"primaryCompletion":38,"completion":70,"start":71,"enrollment":72,"conditions":73,"interventions":76},"ACTIVE_NOT_RECRUITING",[50],"2026-09-01","2024-11-26",28,[20,74,75],"Hypoglycemia, Reactive","Bariatric Surgery",[39],{"trials":78,"activeCount":58},[],{"intervention":44,"totalTrials":54,"cells":80},{"EARLY_PHASE1":81,"PHASE1":83,"PHASE2":85,"PHASE3":87,"PHASE4":89,"NA":91},{"trials":82,"activeCount":58},[],{"trials":84,"activeCount":58},[],{"trials":86,"activeCount":58},[],{"trials":88,"activeCount":58},[],{"trials":90,"activeCount":58},[],{"trials":92,"activeCount":54,"soonestReadout":43},[93],{"nctId":41,"briefTitle":42,"status":68,"phases":94,"primaryCompletion":43,"completion":43,"start":95,"enrollment":96,"conditions":97,"interventions":98},[],"2020-08-11",33,[20],[44],{"intervention":100,"totalTrials":54,"cells":101},"Pramlintide",{"EARLY_PHASE1":102,"PHASE1":104,"PHASE2":106,"PHASE3":108,"PHASE4":110,"NA":124},{"trials":103,"activeCount":58},[],{"trials":105,"activeCount":58},[],{"trials":107,"activeCount":58},[],{"trials":109,"activeCount":58},[],{"trials":111,"activeCount":58},[112],{"nctId":113,"briefTitle":114,"status":115,"phases":116,"primaryCompletion":117,"completion":118,"start":119,"enrollment":120,"conditions":121,"interventions":123},"NCT01841359","Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery","COMPLETED",[50],"2016-07","2022-02-08","2010-02-02",22,[20,122],"Evidence of Previous Gastric Surgery",[100],{"trials":125,"activeCount":58},[],{"intervention":127,"totalTrials":54,"cells":128},"Calcitriol",{"EARLY_PHASE1":129,"PHASE1":131,"PHASE2":133,"PHASE3":135,"PHASE4":137,"NA":153},{"trials":130,"activeCount":58},[],{"trials":132,"activeCount":58},[],{"trials":134,"activeCount":58},[],{"trials":136,"activeCount":58},[],{"trials":138,"activeCount":58},[139],{"nctId":140,"briefTitle":141,"status":115,"phases":142,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":146,"interventions":151},"NCT00752102","Vitamin D and Coronary Calcification Study",[50],"2013-10","2008-09",44,[147,148,149,150],"Chronic Kidney Disease","Vitamin D Deficiency","Coronary Calcification","Disorders of Calcium and Bone Metabolism",[127,152],"Paricalcitol",{"trials":154,"activeCount":58},[],{"intervention":152,"totalTrials":54,"cells":156},{"EARLY_PHASE1":157,"PHASE1":159,"PHASE2":161,"PHASE3":163,"PHASE4":165,"NA":171},{"trials":158,"activeCount":58},[],{"trials":160,"activeCount":58},[],{"trials":162,"activeCount":58},[],{"trials":164,"activeCount":58},[],{"trials":166,"activeCount":58},[167],{"nctId":140,"briefTitle":141,"status":115,"phases":168,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":169,"interventions":170},[50],[147,148,149,150],[127,152],{"trials":172,"activeCount":58},[],{"intervention":174,"totalTrials":54,"cells":175},"Exenatide",{"EARLY_PHASE1":176,"PHASE1":178,"PHASE2":180,"PHASE3":182,"PHASE4":184,"NA":196},{"trials":177,"activeCount":58},[],{"trials":179,"activeCount":58},[],{"trials":181,"activeCount":58},[],{"trials":183,"activeCount":58},[],{"trials":185,"activeCount":58},[186],{"nctId":187,"briefTitle":188,"status":115,"phases":189,"primaryCompletion":190,"completion":190,"start":191,"enrollment":192,"conditions":193,"interventions":194},"NCT00353834","The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes",[50],"2010-09","2006-08",72,[28],[174,195],"Glargine Insulin",{"trials":197,"activeCount":58},[],{"intervention":195,"totalTrials":54,"cells":199},{"EARLY_PHASE1":200,"PHASE1":202,"PHASE2":204,"PHASE3":206,"PHASE4":208,"NA":214},{"trials":201,"activeCount":58},[],{"trials":203,"activeCount":58},[],{"trials":205,"activeCount":58},[],{"trials":207,"activeCount":58},[],{"trials":209,"activeCount":58},[210],{"nctId":187,"briefTitle":188,"status":115,"phases":211,"primaryCompletion":190,"completion":190,"start":191,"enrollment":192,"conditions":212,"interventions":213},[50],[28],[174,195],{"trials":215,"activeCount":58},[],{"intervention":217,"totalTrials":54,"cells":218},"Canagliflozin",{"EARLY_PHASE1":219,"PHASE1":221,"PHASE2":223,"PHASE3":225,"PHASE4":227,"NA":239},{"trials":220,"activeCount":58},[],{"trials":222,"activeCount":58},[],{"trials":224,"activeCount":58},[],{"trials":226,"activeCount":58},[],{"trials":228,"activeCount":58},[229],{"nctId":230,"briefTitle":231,"status":232,"phases":233,"primaryCompletion":234,"completion":234,"start":235,"enrollment":58,"conditions":236,"interventions":238},"NCT02597309","The Effect of add-on Canagliflozin in Patients With Type 2 Diabetes Treated With U-500 Insulin","WITHDRAWN",[50],"2017-07","2015-11",[237],"Diabetes, Obesity",[217],{"trials":240,"activeCount":58},[],{"intervention":242,"totalTrials":54,"cells":243},"Glargine",{"EARLY_PHASE1":244,"PHASE1":246,"PHASE2":248,"PHASE3":250,"PHASE4":252,"NA":263},{"trials":245,"activeCount":58},[],{"trials":247,"activeCount":58},[],{"trials":249,"activeCount":58},[],{"trials":251,"activeCount":58},[],{"trials":253,"activeCount":58},[254],{"nctId":255,"briefTitle":256,"status":115,"phases":257,"primaryCompletion":258,"completion":258,"start":259,"enrollment":260,"conditions":261,"interventions":262},"NCT01480843","Simplified Insulin Protocol Using Lantus in Elderly",[50],"2015-09","2011-06",65,[22],[242],{"trials":264,"activeCount":58},[],{"intervention":266,"totalTrials":9,"cells":267},"Salsalate",{"EARLY_PHASE1":268,"PHASE1":270,"PHASE2":272,"PHASE3":293,"PHASE4":325,"NA":327},{"trials":269,"activeCount":58},[],{"trials":271,"activeCount":58},[],{"trials":273,"activeCount":58},[274,283],{"nctId":275,"briefTitle":276,"status":115,"phases":277,"primaryCompletion":278,"completion":278,"start":279,"enrollment":280,"conditions":281,"interventions":282},"NCT00258128","Effect of Salicylate on Glucose Metabolism in Insulin Resistance States",[47,48],"2008-05","2000-01",17,[32],[266],{"nctId":284,"briefTitle":285,"status":115,"phases":286,"primaryCompletion":287,"start":288,"enrollment":289,"conditions":290,"interventions":291},"NCT00258115","The Study of Inflammation on Blood Glucose Levels in Obese People",[48],"2007-10","2003-12",20,[15],[292],"salsalate",{"trials":294,"activeCount":58},[295,305,315],{"nctId":296,"briefTitle":297,"status":115,"phases":298,"primaryCompletion":299,"completion":300,"start":301,"enrollment":302,"conditions":303,"interventions":304},"NCT00392678","Targeting INflammation Using SALsalate in Type 2 Diabetes (TINSAL-T2D)",[48,49],"2008-07","2010-12","2006-10",277,[25],[266],{"nctId":306,"briefTitle":307,"status":115,"phases":308,"primaryCompletion":309,"start":310,"enrollment":311,"conditions":312,"interventions":313},"NCT00799643","Targeting Inflammation Using Salsalate for Type 2 Diabetes-Stage II",[48,49],"2012-09","2008-11",638,[28],[266,314],"Salsalate Placebo",{"nctId":316,"briefTitle":317,"status":115,"phases":318,"primaryCompletion":319,"completion":117,"start":144,"enrollment":320,"conditions":321,"interventions":324},"NCT00624923","Targeting Inflammation Using Salsalate in CardioVascular Disease",[48,49],"2015-01",340,[322,323],"Coronary Artery Disease","Overweight",[266],{"trials":326,"activeCount":58},[],{"trials":328,"activeCount":58},[],{"intervention":330,"totalTrials":54,"cells":331},"Metformin Extended Release Oral",{"EARLY_PHASE1":332,"PHASE1":334,"PHASE2":336,"PHASE3":338,"PHASE4":351,"NA":353},{"trials":333,"activeCount":58},[],{"trials":335,"activeCount":58},[],{"trials":337,"activeCount":58},[],{"trials":339,"activeCount":58},[340],{"nctId":341,"briefTitle":342,"status":115,"phases":343,"primaryCompletion":344,"completion":344,"start":345,"enrollment":346,"conditions":347,"interventions":349},"NCT04409795","Oral Hypoglycemic Therapy for Monogenic Variant Carriers of the Joslin Medalist Study",[48,49],"2024-12-31","2021-08-26",3,[17,348],"Monogenic Diabetes",[330,350],"Sitagliptin",{"trials":352,"activeCount":58},[],{"trials":354,"activeCount":58},[],{"intervention":350,"totalTrials":54,"cells":356},{"EARLY_PHASE1":357,"PHASE1":359,"PHASE2":361,"PHASE3":363,"PHASE4":369,"NA":371},{"trials":358,"activeCount":58},[],{"trials":360,"activeCount":58},[],{"trials":362,"activeCount":58},[],{"trials":364,"activeCount":58},[365],{"nctId":341,"briefTitle":342,"status":115,"phases":366,"primaryCompletion":344,"completion":344,"start":345,"enrollment":346,"conditions":367,"interventions":368},[48,49],[17,348],[330,350],{"trials":370,"activeCount":58},[],{"trials":372,"activeCount":58},[],{"intervention":374,"totalTrials":54,"cells":375},"CIIIT",{"EARLY_PHASE1":376,"PHASE1":378,"PHASE2":380,"PHASE3":382,"PHASE4":395,"NA":397},{"trials":377,"activeCount":58},[],{"trials":379,"activeCount":58},[],{"trials":381,"activeCount":58},[],{"trials":383,"activeCount":58},[384],{"nctId":385,"briefTitle":386,"status":115,"phases":387,"completion":388,"start":389,"enrollment":390,"conditions":391,"interventions":394},"NCT00594152","Anti-Nephropathic Effects of Chronic Intermittent Intravenous Insulin Therapy (CIIIT)",[49],"1995-01","1993-01",71,[392,393],"Diabetic Nephropathy","Diabetic Retinopathy",[374],{"trials":396,"activeCount":58},[],{"trials":398,"activeCount":58},[],{"intervention":314,"totalTrials":54,"cells":400},{"EARLY_PHASE1":401,"PHASE1":403,"PHASE2":405,"PHASE3":407,"PHASE4":413,"NA":415},{"trials":402,"activeCount":58},[],{"trials":404,"activeCount":58},[],{"trials":406,"activeCount":58},[],{"trials":408,"activeCount":58},[409],{"nctId":306,"briefTitle":307,"status":115,"phases":410,"primaryCompletion":309,"start":310,"enrollment":311,"conditions":411,"interventions":412},[48,49],[28],[266,314],{"trials":414,"activeCount":58},[],{"trials":416,"activeCount":58},[],{"intervention":418,"totalTrials":54,"cells":419},"Betaine",{"EARLY_PHASE1":420,"PHASE1":422,"PHASE2":424,"PHASE3":436,"PHASE4":438,"NA":440},{"trials":421,"activeCount":58},[],{"trials":423,"activeCount":58},[],{"trials":425,"activeCount":58},[426],{"nctId":427,"briefTitle":428,"status":115,"phases":429,"primaryCompletion":430,"completion":431,"start":432,"enrollment":72,"conditions":433,"interventions":435},"NCT01950039","Metabolic Effects of Betaine Supplementation",[48],"2017-12","2018-08","2014-01",[15,434],"Dysglycemia",[418],{"trials":437,"activeCount":58},[],{"trials":439,"activeCount":58},[],{"trials":441,"activeCount":58},[],{"intervention":443,"totalTrials":54,"cells":444},"glucagon",{"EARLY_PHASE1":445,"PHASE1":447,"PHASE2":449,"PHASE3":461,"PHASE4":463,"NA":465},{"trials":446,"activeCount":58},[],{"trials":448,"activeCount":58},[],{"trials":450,"activeCount":58},[451],{"nctId":452,"briefTitle":453,"status":115,"phases":454,"primaryCompletion":455,"completion":455,"start":456,"enrollment":457,"conditions":458,"interventions":460},"NCT03255629","Closed-Loop Glucagon Pump for Treatment of Post-Bariatric Hypoglycemia",[47,48],"2018-08-22","2017-09-19",18,[459],"Post-bariatric Hypoglycemia",[443],{"trials":462,"activeCount":58},[],{"trials":464,"activeCount":58},[],{"trials":466,"activeCount":58},[],{"intervention":468,"totalTrials":54,"cells":469},"Allopurinol",{"EARLY_PHASE1":470,"PHASE1":472,"PHASE2":474,"PHASE3":476,"PHASE4":478,"NA":480},{"trials":471,"activeCount":58},[],{"trials":473,"activeCount":58},[],{"trials":475,"activeCount":58},[],{"trials":477,"activeCount":58},[],{"trials":479,"activeCount":58},[],{"trials":481,"activeCount":58},[482],{"nctId":483,"briefTitle":484,"status":115,"phases":485,"primaryCompletion":486,"completion":487,"start":488,"enrollment":489,"conditions":490,"interventions":492},"NCT03334318","PERL Continuous Glucose Monitoring (CGM) Study",[],"2019-08-31","2021-12-31","2017-10-01",175,[491],"Diabetic Nephropathies",[468],{"intervention":494,"totalTrials":54,"cells":495},"Lispro",{"EARLY_PHASE1":496,"PHASE1":498,"PHASE2":500,"PHASE3":502,"PHASE4":504,"NA":506},{"trials":497,"activeCount":58},[],{"trials":499,"activeCount":58},[],{"trials":501,"activeCount":58},[],{"trials":503,"activeCount":58},[],{"trials":505,"activeCount":58},[],{"trials":507,"activeCount":58},[508],{"nctId":509,"briefTitle":510,"status":115,"phases":511,"primaryCompletion":512,"completion":512,"start":513,"enrollment":23,"conditions":514,"interventions":515},"NCT02248454","Insulin Bolus Required for High Fat Foods in Type 1 Diabetes",[51],"2015-04","2014-09",[17],[494],{"intervention":517,"totalTrials":54,"cells":518},"Insulin Aspart versus Insulin Lispro",{"EARLY_PHASE1":519,"PHASE1":521,"PHASE2":523,"PHASE3":525,"PHASE4":527,"NA":529},{"trials":520,"activeCount":58},[],{"trials":522,"activeCount":58},[],{"trials":524,"activeCount":58},[],{"trials":526,"activeCount":58},[],{"trials":528,"activeCount":58},[],{"trials":530,"activeCount":58},[531],{"nctId":532,"briefTitle":533,"status":534,"phases":535,"primaryCompletion":536,"completion":536,"start":537,"enrollment":33,"conditions":538,"interventions":539},"NCT00428207","Glycemic Stability of Insulin Aspart Versus Insulin Lispro in Insulin Pump Therapy","TERMINATED",[51],"2008-08","2007-02",[30],[517,540],"Insulin Lispro versus Insulin Aspart",{"intervention":540,"totalTrials":54,"cells":542},{"EARLY_PHASE1":543,"PHASE1":545,"PHASE2":547,"PHASE3":549,"PHASE4":551,"NA":553},{"trials":544,"activeCount":58},[],{"trials":546,"activeCount":58},[],{"trials":548,"activeCount":58},[],{"trials":550,"activeCount":58},[],{"trials":552,"activeCount":58},[],{"trials":554,"activeCount":58},[555],{"nctId":532,"briefTitle":533,"status":534,"phases":556,"primaryCompletion":536,"completion":536,"start":537,"enrollment":33,"conditions":557,"interventions":558},[51],[30],[517,540]]